Baan Abdulatif Mtashar

@uomustansiriyah.edu.iq

Lecturer / Microbiology department/ college of medicine
Lecturer / Mustansiriyiah university/ college of medicine

Baan Abdulatif Mtashar


                        Download Compact PDF  
https://researchid.co/dr.baan79

RESEARCH, TEACHING, or OTHER INTERESTS

General Immunology and Microbiology, Biochemistry, Genetics and Molecular Biology, Cancer Research, Virology
7

Scopus Publications

Scopus Publications

  • Immune-biomarker signature predicts early molecular response in Iraqi chronic myeloid leukemia patients receiving front-line tyrosine-kinase inhibitors
    Z. A. Shabeeb, Y. F. Faraj, B. A. Mtashar, M. S. Hussein, A. F. Hasan
    Regulatory Mechanisms in Biosystems, 2025
    Chronic myeloid leukemia (CML) is characterized by ABL1::BCR-driven leukemogenesis. Although tyrosine-kinase inhib i tors (TKIs) have transformed prognosis, predicting early molecular response (EMR) and treatment-free remission (TFR) remains clinically challenging. Immune mediators such as interleukin-2 (IL)-2, IL-7, and perforin may serve as biomarkers reflecting host - leukemia interactions. This study aimed to evaluate the diagnostic and prognostic potential of IL-2, IL-7, and perforin as predictive biomarker s in Iraqi patients with CML. A total of 215 participants were enrolled, including healthy controls (n = 55), newly diagnosed CML patients (n = 20), treatment-free remission patients (TFR) (n = 20), and patients receiving imatinib (n = 30), nilotinib (n = 30), or bosutinib (n = 30). Serum IL-2, IL-7, and perforin levels were quantified by ELISA, and molecular responses were monitored using qRT-PCR standardized to the International Scale. ROC analysis determined optimal biomarker cut-offs and predictive performance for EMR and TFR. The results indicated that IL-2 and IL-7 were significantly elevated in newly diagnosed CML patients (312.4 ± 133.2 and 158.9 ± 108.4 pg/mL) compared to controls (104.6 ± 50.7 and 53.8 ± 8.1 pg/mL, P < 0.0001). Perforin was markedly reduced (1.6 ± 0.9 and 8.7 ± 5.2 ng/mL). ROC analysis revealed IL-2 (AUC = 0.980), IL-7 (AUC = 1.000), and perforin (inverse AUC < 0.00 1 ) as highly discriminative for diagnosis, while perforin (AUC = 0.999, cut-off 3.76 ng/mL) emerged as the strongest predictor of TFR. An immune - biomarker panel integrating high IL-2/IL-7 and depleted perforin at diagnosis effectively predicts EMR and sustained TFR. Incorporating immune profiling into CML ma n agement may refine early risk stratification and enable personalized TKI selection.
  • Interplaying Correlation of Some Genetic and Inflammatory Factors among Patients with Polycythemia Vera
    Yusra Ghiath, Baan Abdulatif Mtashar, Noor AL-Huda Salah AL-Zuhairy, Mohanad Salam Hussein, Ahmed Flayyih Hasan
    Asian Journal of Dairy and Food Research, 2025
    Background: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by the overproduction of red blood cells. A key feature of PV is the dysregulation of cytokine networks, with elevated levels of various pro-inflammatory cytokines contributing to disease progression. The JAK2 mutation, a common genetic driver of PV, stimulates the production of these cytokines, leading to increased cell proliferation, inhibited apoptosis and inflammation. Estimation of IL-12 and IL-21 Level and study the correlation between of theses cytokine with JAK2 V617F and hematological parameters. Methods: This study investigated 60 patients diagnosed with polycythemia vera (PV) at the National Center of Hematology between January 2023 and July 2024. The patient group consisted of 33 females and 27 males, with ages ranging from 18 to 75 years. Detection JAK2 V617F using Poly chain reaction (PCR) as well as estimation of IL-12 and IL-21 by sandwich ELISA technique. Result: In this Study 31 of PV patients detected as JAK2 V 617F Negative while 29 patients were positive. Also, this study examined the role of IL-12 and IL-21 in polycythemia vera (PV). Patients with the JAK2 V617F mutation had significantly higher IL-12 levels, suggesting a strong association. However, no significant differences were found in IL-21 levels between groups. Additionally, WBC count and platelets count were positively correlated with IL-21.
  • Investigation of TYMS (rs 2853542) polymorphism and Cytomegalovirus in patients with Acute Lymphoblastic Leukemia
    Elaf Zuhair Hmeed, Baan Abdulatif Mtashar, Yusra Ghiath, Shakir H. Mohammed Al-Alwany, Mohanad Salam Hussein, et al.
    Journal of Bioscience and Applied Research, 2025
  • Light transmission aggregometry: Useful but difficult diagnostic tool
    Yusra Ghiath Yaseen, Baan Abdulatif Mtashar, Abbas Hashim Abdulsalam, Yusur Falah Faraj
    Iraqi Journal of Hematology, 2024
  • Menorrhagia in inherited bleeding disorders in Iraqi women
    Yusra Ghiath Yaseen, Elaf Zuhair Hmeed, Nidal Karim Al Rahal, Baan Abdulatif Mtashar
    Iraqi Journal of Hematology, 2024
    BACKGROUND: Menorrhagia, or excessive menstrual bleeding, is a common symptom in women with inherited bleeding disorders; they are conditions where the blood ability to clot is impaired. Some of the common bleeding disorders include von Willebrand disease (VWD), clotting factor deficiencies, and platelet function disorders. OBJECTIVE: To assess different types of inherited bleeding disorders in women with menorrhagia referred to the National Center of Hematology/Mustansiriyah University in Baghdad/Iraq. PATIENTS AND METHODS: A prospective study was carried out on 193 women who had experienced menorrhagia for a duration of 3 years, from 2020 to 2023. These women sought consultation at the National Centre of Hematology/Mustansiriyah University. All participants were diagnosed through various laboratory tests, including complete blood count, blood film, blood group and Rh, bleeding time, prothrombin time, activated partial thromboplastin time, fibrinogen level, factor assay, von Willebrand factor antigen using ELISA technique, ristocetin cofactor, and platelet function test. RESULTS: Out of the 193 women with menorrhagia who participated in this study, the majority of whom had an unidentified cause (36.3%), followed by VWD (30.1%) and platelet function disorders (21.2%). Other bleeding disorders ( thrombocytopenia and factors deficiencies) were 5.7% and 6.7%, respectively. Furthermore, the results showed that there was a significant difference in family history and consanguinity between patients with a hereditary bleeding disorder and nonhereditary bleeding disorder (P < 0.001). CONCLUSIONS: Fifty eight percent of females with Menorrhagia in this study have inherited bleeding disorders(IBDs), VWD, and thrombasthenia account for 51.3% are the most common causes of inherit bleeding disorder (IBD). Consanguineous marriage should be discouraged in Iraqi society to reduce such inherited diseases.
  • Biochemical and breakpoint cluster region-c-ABL oncogene 1 polymorphism study among Iraqi patients with chronic myeloid leukemia
    Aseel Majeed Hameed, Zairi Amira, Shakir H. Mohammed Al-Alwany, Baan A. Mtashar
    Iraqi Journal of Hematology, 2023
    BACKGROUND: Chronic myeloid leukemia (CML) has been well recognized as an exemplary instance of a malignant disease characterized by a distinctive molecular occurrence, namely the presence of the breakpoint cluster region (BCR)-c-ABL oncogene 1 (ABL1) oncogene. The Philadelphia chromosome gives rise to an anomalous fusion gene characterized by atypical kinase activity, resulting in the accumulation of reactive oxygen species and genetic instability that holds significance in the advancement of diseases. OBJECTIVE: The objective of this study was to investigate the detection rate of BCR-ABL1 polymorphism and BCR protein level in a group of Iraqi patients with CML. MATERIALS AND METHODS: This study has been carried out on 150 specimens, 120 patients subjected to CML included 20 patients diagnosed as newly diagnosis CML and 100 patients treated with CML. In addition to 30 apparently healthy persons as a control group (normal persons) from the National Center of Hematology/Mustansiryiah University/Baghdad, 65 out of 100 patients on imatinib while 35 nonimatinib (nilotinib and bosutinib). Fresh whole blood and serum were obtained from all patients and controls. We used total DNA genomic extraction extracted from ethylenediaminetetraacetic acid blood for genetic detection of Bcr/Abl Genes Polymorphism by sequencing technique in patients with CML and apparently control groups and used serum for biochemical tests include urea, lactate dehydrogenase (LDH), aspartate transaminase (AST), alanine transaminase (ALT), and creatinine using biochemicals methods (colorimetric and kinetic), respectively, as well as detection BCR protein level using sandwich enzyme-linked immunosorbent assays technique. RESULTS: According to age and sex, the patients’ groups were matching with the control group. Regarding the biochemical parameters (urea creatinine, ALT, AST, and LDH) serum level, there are no significant differences among new diagnosis CML, patients respond to treatments and failure group except in serum level of creatinine between new diagnosis CML group and failure group, there are significant differences (P = 0.01). The present results showed that DNA polymorphism distribution was according to C\\C; G\\C; A\\T; and A\\A were 32%, 26%, 18%, and 24%, respectively, in patients with CML and 28%; 20%;12%; and 40%, respectively, in the control group. There are significant statistical differences (P < 0.05) between different groups according to the genotyping of BCR\\ABL, the results obtained from the sequenced 429 bp fragments, and the detailed positions of the observed variations are described in the NCBI reference sequences (rs766724113). The samples were submitted in NCBI, and the accession number of nucleotide sequences of BCR\\ABL as new recording: LC 775148, LC 775149, and LC 775150, while regarding with BCR protein, there are significant differences in level between new diagnosis CML and CML on treatment and control groups, P < 0.001 for each comparison while there are no significant differences between treated group and control group (P = 0.729). CONCLUSION: The present results indicate that BCR-ABL1 polymorphism and BCR protein level in a group of Iraqi patients with CML may play a role in the tumor biology of the examined subset of CML and may contributed to their development.
  • Influence of RANKL and OPG in Hemophilic arthropathy
    Yussur Falah Faraj, Fatma Abd Alhamza Obed, Baan Abdulatif Mtashar, Nidal Karim Al-Rahal, Jaafar Hussien Kareem
    Research Journal of Pharmacy and Technology, 2022
    Background: Hemophilia is a bleeding disorder characterized by recurrent bleeding, especially in joints (hemarthrosis), leading to destructive effect to the most of joint components, resulting in synovitis, osteochondral degeneration, and eventually, end-stage hemophilic arthropathy. Objective: Since few published data exist about the influence of OPG (Osteoprotegrin) and RANKL (receptor activator of nuclear factor-kappa B ligand) in haemophilic arthropathy, the present study is conducted to investigate their serum level in hemophilic patients. Methodology: This study has been carried out on Iraqi patients with hemophilia in the National Center of Hematology/Mustansiriyah University. Forty male patients involved in this study with a range of (11-44) years old, Hemophilia A affected 25 of them, while the other 15 were hemophilia B. Along with patient group, 20 healthy subjects with matched age and gender were involved as control group. The presence and severity of arthropathy among patients was determined based activated partial thromboplastin time (aPTT)) in hemophilic patients, while RANKL and OPG were determined in the serum samples of healthy and patient subjects. Result: The serum level of RANKL in Hemophilia A patients was (204.6pg/ml) is significantly (p0.001) higher than in control (164.5pg/ml) and in Hemophilia B patients was (200pg/ml). While the serum level of OPG in Hemophilia A patients was (67.2pg/ml) is significantly (p0.002) higher than in control (30.21pg /ml) and in Hemophilia B patients (48.85pg/ml). Conclusion: It can be concluded that this system RANKL, RANK, and OPG are important for the metabolism of bones.